<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02581137</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2015-01733</org_study_id>
    <secondary_id>NCI-2015-01733</secondary_id>
    <secondary_id>HHSN2612012000311</secondary_id>
    <secondary_id>N01-CN-2012-00031</secondary_id>
    <secondary_id>1510157567</secondary_id>
    <secondary_id>UAZ2015-05-02</secondary_id>
    <secondary_id>N01CN00031</secondary_id>
    <secondary_id>P30CA023074</secondary_id>
    <nct_id>NCT02581137</nct_id>
  </id_info>
  <brief_title>Metformin Hydrochloride in Preventing Oral Cancer in Patients With an Oral Premalignant Lesion</brief_title>
  <official_title>M4OC-Prevent: Metformin for Oral Cancer Prevention</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase IIa trial studies how well metformin hydrochloride works in preventing oral cancer
      in patients with an oral premalignant lesion (oral leukoplakia or erythroplakia). Oral
      premalignant lesions look like red or whitish plaques or lesions in the mouth that do not rub
      off and can be associated with a higher risk of cancer. Metformin hydrochloride may help
      prevent oral cancer from forming in patients with an oral premalignant lesion.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the clinical response of oral premalignant lesions to 12-14 weeks of
      metformin (metformin hydrochloride) intervention.

      SECONDARY OBJECTIVES:

      I. Histologic response to metformin intervention in the target lesion. II. Tissue-based
      biomarkers: metformin effect on cell proliferation and its molecular targets in the target
      lesion and in the normal tissue (marker of cell proliferation, Ki67, molecular targets of
      metformin, including, in order of priority, phosphorylated ribosomal protein S6 kinase [pS6],
      phosphorylated v-akt murine thymoma viral oncogene homolog 1 [pAKT]S473, phosphorylated
      eukaryotic translation initiation factor 4E-binding protein 1 [p4EBP], phosphorylated
      acetyl-CoA carboxylase alpha [pACC]).

      III. Tissue-based biomarkers: expression of dysregulated molecular mechanisms and organic
      cation transporter 3 (OCT 3) in the target lesion and in the normal tissue, including, in
      order of priority, epidermal growth factor receptor (EGFR), phosphorylated (p)EGFR, tumor
      protein 53 (p53), phosphatase and tensin homolog (PTEN), phosphorylated mitogen-activated
      protein kinase 1 (pERK), cyclin-dependent kinase inhibitor 2A (p16), and OCT3.

      IV. Tissue-based biomarkers: targeted analysis of cancer-associated genes in the target
      lesion and blood deoxyribonucleic acid (DNA).

      V. Serum and saliva based biomarkers: metformin effect on serum metabolic markers (C-peptide,
      glycosylated hemoglobin [HbA1c]).

      VI. Serum and saliva based biomarkers: metformin concentrations in serum and saliva.

      VII Serum and saliva based biomarkers: metformin effect on serum and saliva inflammatory and
      angiogenic cytokines, including interleukin (IL)-6, IL-8, growth-related oncogene-1 (GRO-1),
      and vascular endothelial growth factor (VEGF).

      EXPLORATORY OBJECTIVES:

      I. To characterize changes in the saliva microbiome before and after metformin intervention,
      including both the absolute microbial load and taxonomic composition.

      II. To evaluate the potential microbiome signatures that are correlated with treatment
      response.

      OUTLINE:

      Patients receive extended-release metformin hydrochloride orally (PO) once daily (QD) for 2
      weeks and then twice daily (BID) for 10-12 weeks. Treatment continues in the absence of
      disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 2-4 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 10, 2016</start_date>
  <primary_completion_date type="Actual">October 12, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Response to Metformin Intervention</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Number of participants with complete and partial clinical response to metformin intervention.
Criteria for complete and partial clinical response are:
Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histologic Response to Metformin Intervention</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Number of participants with complete and partial histologic response to metformin intervention.
Criteria for complete and partial histologic response are:
Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion.
Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Cell Proliferation and Its Molecular Targets</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Frequent Dysregulated Molecular Mechanisms and OCT Expression</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any of the expression of frequent dysregulated mechanisms and OCT3 level are associated with the clinical response to metformin hydrochloride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of Genomic Alterations on the Biological and Biochemical Consequences and Clinical Response to Metformin Hydrochloride</measure>
    <time_frame>Up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any genomic alterations are associated with the clinical response to metformin hydrochloride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Measurements of Metformin Hydrochloride Concentrations in Serum and Saliva</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum Metabolic Markers</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Serum and Saliva Inflammatory and Angiogenic Cytokines</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in Saliva Microbiome Analyzed Using Flow Cytometry</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>This will characterize changes in the saliva microbiome before and after metformin intervention, including both the absolute microbial load and taxonomic composition. Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), permutational multivariate analysis of variance (PERMANOVA) will be used.</description>
  </other_outcome>
  <other_outcome>
    <measure>Microbiome Signatures Correlated With Treatment Response</measure>
    <time_frame>Baseline to up to 14 weeks</time_frame>
    <description>Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), PERMANOVA will be used.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">26</enrollment>
  <condition>Erythroplakia</condition>
  <condition>Hyperplasia</condition>
  <condition>Oral Cavity Carcinoma</condition>
  <condition>Oral Leukoplakia</condition>
  <arm_group>
    <arm_group_label>Prevention (extended-release metformin hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Laboratory Biomarker Analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Prevention (extended-release metformin hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin Hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Prevention (extended-release metformin hydrochloride)</arm_group_label>
    <other_name>APO-Metformin</other_name>
    <other_name>Cidophage</other_name>
    <other_name>Dimefor</other_name>
    <other_name>Glifage</other_name>
    <other_name>Glucoformin</other_name>
    <other_name>Glucophage</other_name>
    <other_name>Glucophage ER</other_name>
    <other_name>Metformin HCl</other_name>
    <other_name>Riomet</other_name>
    <other_name>Siofor</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants with oral leukoplakia or erythroplakia with mild, moderate, or severe
             histologic dysplasia, or hyperplasia not associated with mechanical factors such as
             ill-fitted dentures

          -  Measurable disease - minimum lesion size of 8 x 3 mm before initial biopsy

          -  Karnofsky performance status &gt;= 70%

          -  Leukocytes &gt;= 3,000/microliter

          -  Absolute neutrophil count &gt;= 1,000/microliter

          -  Platelets &gt;= 100,000/microliter

          -  Total bilirubin =&lt; 1.5 × institutional upper limit of normal (ULN)

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
             =&lt;1.5 × institutional ULN

          -  eGFR &gt; 40 mL/min using the Cockcroft-Gault equation

          -  Life expectancy &gt; 3 months

          -  Willing to use adequate contraception (barrier method, abstinence, subject has had a
             vasectomy or partner is using effective birth control or is postmenopausal) for the
             duration of study participation

          -  Ability to take oral medication

          -  Ability to understand and the willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Patients with diabetes who are taking insulin or oral agents

          -  History of diabetic ketoacidosis

          -  Participants may not be receiving any other investigational agents within past 3
             months

          -  History of allergic reactions attributed to compounds of similar chemical composition
             to metformin or prior use of metformin within the last year

          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active
             infection, human immunodeficiency virus (HIV)-positive, symptomatic congestive heart
             failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social
             situations that would limit compliance with study requirements

          -  Oral carcinoma in situ

          -  History of chronic alcohol use or abuse defined as any one of the following: a)
             average consumption of 3 or more alcohol containing beverages daily in the past 12
             months; b) consumption of 7 or more alcoholic beverages within a 24 hour (hr) period
             in the past 12 months

          -  Glycated hemoglobin (HbA1c) &gt; 8%

          -  Pregnancy or nursing women

          -  Acute or chronic liver disease, evidence of hepatitis (infectious or autoimmune),
             cirrhosis or portal hypertension

          -  History of renal disease

          -  History of prior head and neck squamous cell carcinoma (HNSCC) unless curatively
             treated for &gt;= 1 year

          -  Have received chemotherapy and/or radiation for any malignancy (excluding non-melanoma
             skin cancer and cancers confined to organs with removal as only treatment) in the past
             2 years; ongoing adjuvant hormonal therapy for breast cancer is allowed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott M Lippman</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Arizona Medical Center-University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota/Masonic Cancer Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BC Cancer Research Centre</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1L3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of British Columbia Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6T 2B5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 19, 2015</study_first_submitted>
  <study_first_submitted_qc>October 19, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <results_first_submitted>April 29, 2019</results_first_submitted>
  <results_first_submitted_qc>April 29, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 23, 2019</results_first_posted>
  <last_update_submitted>May 2, 2020</last_update_submitted>
  <last_update_submitted_qc>May 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Leukoplakia</mesh_term>
    <mesh_term>Leukoplakia, Oral</mesh_term>
    <mesh_term>Hyperplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/37/NCT02581137/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Prevention (Extended-release Metformin Hydrochloride)</title>
          <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Metformin Hydrochloride: Given PO</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Prevention (Extended-release Metformin Hydrochloride)</title>
          <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Metformin Hydrochloride: Given PO</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="26"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Response to Metformin Intervention</title>
        <description>Number of participants with complete and partial clinical response to metformin intervention.
Criteria for complete and partial clinical response are:
Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Extended-release Metformin Hydrochloride)</title>
            <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Metformin Hydrochloride: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Response to Metformin Intervention</title>
          <description>Number of participants with complete and partial clinical response to metformin intervention.
Criteria for complete and partial clinical response are:
Complete Response (CR): Disappearance of all evidence of lesion(s). Partial Response (PR): Greater than or equal to 50% reduction in the sum of the products of diameters of lesion(s) measurable at baseline. Non-measurable lesion(s) may not increase greater than or equal to 25% in size and no new lesion may appear.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Histologic Response to Metformin Intervention</title>
        <description>Number of participants with complete and partial histologic response to metformin intervention.
Criteria for complete and partial histologic response are:
Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion.
Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Prevention (Extended-release Metformin Hydrochloride)</title>
            <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Metformin Hydrochloride: Given PO</description>
          </group>
        </group_list>
        <measure>
          <title>Histologic Response to Metformin Intervention</title>
          <description>Number of participants with complete and partial histologic response to metformin intervention.
Criteria for complete and partial histologic response are:
Complete Response (CR): Complete reversal of dysplasia or hyperplasia to normal epithelium in the target lesion.
Partial Response (PR): Improvement of the degree of dysplasia or hyperplasia in the target lesion.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Cell Proliferation and Its Molecular Targets</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Frequent Dysregulated Molecular Mechanisms and OCT Expression</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any of the expression of frequent dysregulated mechanisms and OCT3 level are associated with the clinical response to metformin hydrochloride.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Impact of Genomic Alterations on the Biological and Biochemical Consequences and Clinical Response to Metformin Hydrochloride</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers. A univariate logistic regression model with the clinical response as the outcome variable will be fitted to explore if any genomic alterations are associated with the clinical response to metformin hydrochloride.</description>
        <time_frame>Up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Measurements of Metformin Hydrochloride Concentrations in Serum and Saliva</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum Metabolic Markers</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Serum and Saliva Inflammatory and Angiogenic Cytokines</title>
        <description>Nonparametric methods, e.g. signed rank test, will be performed to evaluate each of the changes in tissue, serum, and saliva markers.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in Saliva Microbiome Analyzed Using Flow Cytometry</title>
        <description>This will characterize changes in the saliva microbiome before and after metformin intervention, including both the absolute microbial load and taxonomic composition. Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), permutational multivariate analysis of variance (PERMANOVA) will be used.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Microbiome Signatures Correlated With Treatment Response</title>
        <description>Will first evaluate changes in alpha diversity among matched pairs using non-parametric analogous Wilcoxon rank-sum test (Mann-Whitney test). To test for significant differences in beta diversity (e.g. if pretreatment and post-treatment samples cluster in principle coordinates analysis space), PERMANOVA will be used.</description>
        <time_frame>Baseline to up to 14 weeks</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Prevention (Extended-release Metformin Hydrochloride)</title>
          <description>Patients receive extended-release metformin hydrochloride PO QD for 2 weeks and then BID for 10-12 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.
Laboratory Biomarker Analysis: Correlative studies
Metformin Hydrochloride: Given PO</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Bloating</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Stomach pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="26"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Sherry Chow</name_or_title>
      <organization>University of Arizona</organization>
      <phone>5206263358</phone>
      <email>schow@azcc.arizona.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

